Capricor Therapeutics, Inc. (CAPR)
Market Cap | 150.94M |
Revenue (ttm) | 27.10M |
Net Income (ttm) | -24.31M |
Shares Out | 31.98M |
EPS (ttm) | -0.83 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 226,428 |
Open | 4.810 |
Previous Close | 4.840 |
Day's Range | 4.660 - 4.820 |
52-Week Range | 2.680 - 8.220 |
Beta | 3.97 |
Analysts | Strong Buy |
Price Target | 21.75 (+360.81%) |
Earnings Date | Aug 5, 2024 |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under... [Read more]
Financial Performance
In 2023, CAPR's revenue was $25.18 million, an increase of 886.81% compared to the previous year's $2.55 million. Losses were -$22.29 million, -23.20% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price forecast is $21.75, which is an increase of 360.81% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/q/l/press3-2495414.jpg)
CORRECTION: Capricor Therapeutics
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor...
![](https://cdn.snapi.dev/images/v1/9/2/press6-2494995.jpg)
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...
![](https://cdn.snapi.dev/images/v1/v/p/press8-2473366.jpg)
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR)...
![](https://cdn.snapi.dev/images/v1/5/9/biotech18-2472157.jpg)
Capricor Advances in DMD Therapy With Positive Study Data
Capricor Therapeutics CAPR, a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year results from the ongoing HOPE-2 open-label extension (OLE) study ...
![](https://cdn.snapi.dev/images/v1/w/o/press19-2428046.jpg)
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024–
![](https://cdn.snapi.dev/images/v1/9/h/conf18-2420977.jpg)
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral session being held on May 9, 2024- SAN DIEGO,...
![](https://cdn.snapi.dev/images/v1/h/g/conf6-2418098.jpg)
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseas...
![](https://cdn.snapi.dev/images/v1/y/h/conf20-2412009.jpg)
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseas...
![](https://cdn.snapi.dev/images/v1/6/n/press10-2388053.jpg)
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility-
![](https://cdn.snapi.dev/images/v1/b/g/conf6-2335106.jpg)
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and preventi...
![](https://cdn.snapi.dev/images/v1/t/l/press1-2310768.jpg)
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Presentation Highlights Positive 24-Month Results from HOPE-2 Open L...
![](https://cdn.snapi.dev/images/v1/e/n/press16-2302257.jpg)
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in Q4 20...
![](https://cdn.snapi.dev/images/v1/h/t/press7-2295723.jpg)
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevent...
![](https://cdn.snapi.dev/images/v1/l/c/conf2-2288427.jpg)
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and preventio...
![](https://cdn.snapi.dev/images/v1/6/g/press6-2283429.jpg)
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
-Cohort B of HOPE-3, Phase 3 Clinical Trial Expected to Complete Enrollment in Second Quarter 2024- SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology c...
![](https://cdn.snapi.dev/images/v1/a/d/press9-2242368.jpg)
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
-Project NextGen Collaboration will Support Capricor's StealthX™ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic-
![](https://cdn.snapi.dev/images/v1/7/u/press16-2191117.jpg)
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
--Favorable Interim Futility Analysis Results-- --Successful Completion Triggers First Milestone Payment Under U.S. Agreement with Nippon Shinyaku--
![](https://cdn.snapi.dev/images/v1/i/p/press1-2157950.jpg)
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy- -On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Wou...
![](https://cdn.snapi.dev/images/v1/h/o/conf14-2144102.jpg)
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea...
![](https://cdn.snapi.dev/images/v1/w/z/press19-2112163.jpg)
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program
SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea...
![](https://cdn.snapi.dev/images/v1/f/x/press17-2096781.jpg)
Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002's Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy-
![](https://cdn.snapi.dev/images/v1/d/l/press1-2083418.jpg)
Capricor Therapeutics Announces $23 Million Registered Direct Offering
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the tre...
![](https://cdn.snapi.dev/images/v1/d/f/press17-2083407.jpg)
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
-FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002's Path Towards a Biologics License Application (BLA)-
![](https://cdn.snapi.dev/images/v1/u/c/press19-2051445.jpg)
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for...
![](https://cdn.snapi.dev/images/v1/b/g/press6-2010479.jpg)
Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-Presented Statistically Significant 24-Month HOPE-2 Open Label Extension Data at the PPMD Annual Conference- -Enrollment Continues to Progress in HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Mus...